falsefalse

Improving Outcomes in Metastatic HER2+ Breast Cancer: Translating Evidence to Clinical Practice - Episode 7

Overview of the HER2+ Metastatic Breast Cancer Treatment Armamentarium

A key opinion leader in breast cancer management shares insight on the treatment armamentarium for patients with HER2+ disease.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Landscape of HER2+ Metastatic Breast Cancer: Patient Overview
    EP. 2: HER2+ Metastatic Breast Cancer: An Evolving Treatment Armamentarium
    EP. 3: HER2+ Metastatic Breast Cancer: Factors in Selecting 2L Therapy and Beyond
    EP. 4: Role of T-DXd in Patients With HER2+ Metastatic Breast Cancer and CNS Metastasis
    EP. 5: HER2+ Breast Cancer With CNS or Leptomeningeal Metastases: Future Directions in Care
    EP. 6: Patient Profile: A 68-Year-Old Woman With HER2+ Metastatic Breast Cancer
    Now Viewing
    EP. 7: Overview of the HER2+ Metastatic Breast Cancer Treatment Armamentarium
    EP. 8: Factors in Selecting Third-Line Therapy for HER2+ Metastatic Breast Cancer
    EP. 9: Role of Brain Metastases and Quality of Life in Treatment Decisionmaking
    EP. 10: Addressing Resistance to HER2-Targeted Therapy in Metastatic Breast Cancer
    EP. 11: HER2+ Metastatic Breast Cancer: Unmet Needs and Future Directions in Care

    Related Content:

    Improving Outcomes in Metastatic HER2+ Breast Cancer: Translating Evidence to Clinical Practice Mays Cancer Center at UT Health San AntonioBreast CancerInsights
    Analysis of PADA-1 Trial Highlights Kinetics and Determinants of ESR1 Mutations in HR+/HER2– Metastatic Breast Cancer
    Navigating the Data: Later-Line Systemic Therapies for HER2+ Metastatic Breast Cancer
    The Impact of Frontline Treatment Selection on Second-line Therapy for EGFR-mutant NSCLC
    x